Zobrazeno 1 - 10
of 265
pro vyhledávání: ''
Autor:
Takao Takahashi, Kazuhiro Yoshida, Nobuhisa Matsuhashi, Nobuhiko Sugito, Yukihiro Akao, Masahiro Fukada, Kazuki Heishima
Publikováno v:
Cancer Science
Cancer‐related microRNAs (miRNAs) are emerging as promising and noninvasive biomarkers for colorectal cancer (CRC). This study aimed to investigate the usefulness of postoperative changes in plasma miR21‐5p levels for recurrence and progressive d
Autor:
Xiaoying Sun, Duanfeng Jiang, Guozhen Zhang, Xiaotao Wang, Qiuyu Mo, Fangping Chen, Qiangqiang Zhao, Min Dong
Publikováno v:
Cancer Science
Diffuse large B cell lymphoma (DLBCL) heterogeneity promotes recurrence and anti‐CD20‐based therapeutic resistance. Previous studies have shown that downregulation of MS4A1/CD20 expression after chemoimmunotherapy with rituximab leads to rituxima
Autor:
Shigeyuki Shichino, Hiromichi Nakajima, Yoshiaki Nakamura, Tetsuya Nakatsura, Satoshi Ueha, Manami Shimomura, Hiroyasu Aoki, Akihiro Sato, Kouji Matsushima, Takayuki Yoshino
Publikováno v:
Cancer Science
With the widespread use of programmed death receptor‐1 (PD‐1) blockade therapy, sensitive and specific predictive biomarkers that guide patient selection are urgently needed. T‐cell receptor (TCR) repertoire, which reflects antitumor T‐cell r
Autor:
Akihiro Sakai, Qingjiang Hu, Koji Ando, Masaki Mori, Yasue Kimura, Ryota Nakanishi, Eiji Oki, Yuichi Hisamatsu, Kazuki Takada, Naomichi Koga, Yoshinao Oda
Publikováno v:
Cancer Science
Signal regulatory protein alpha (SIRPα) is a type I transmembrane protein that inhibits macrophage phagocytosis of tumor cells upon interaction with CD47, and the CD47‐SIRPα pathway acts as an immune checkpoint factor in cancers. This study aims
Autor:
Shinichiro Takahashi, Toshihiro Suzuki, Katsuhiko Uesaka, Motohiro Kojima, Satoshi Okubo, Yasuhiro Shimizu, Hirochika Toyama, Genichiro Ishii, Naoto Gotohda, Soichiro Morinaga, Masayoshi Hioki
Publikováno v:
Cancer Science
Several therapeutic regimens, including neoadjuvant chemoradiation therapy (NACRT), have been reported to serve as anticancer immune effectors. However, there remain insufficient data regarding the immune response after NACRT in pancreatic ductal ade
Autor:
Yusuke Ono, Ryohei Katayama, Noriko Yanagitani, Ken Uchibori, Makoto Nishio, Satoru Kitazono, Ryo Ariyasu, Ryohei Yoshida, Yusuke Mizukami, Mika Tsukahara, Takaaki Sasaki, Kazuma Kiyotani, Yuichi Ishikawa, Naoya Fujita, Hironori Ninomiya
Publikováno v:
Cancer Science
Osimertinib is a third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) that is effective in treating both naïve and T790M‐mutated EGFR‐TKI‐resistant non–small cell lung cancer patients. The EGFR C797S mut
Autor:
Naoki Hiki, Masahiro Niihara, Takafumi Sangai, Marie Washio, Nobuyuki Nishizawa, Yusuke Kumamoto, Takafumi Soeno, Mikiko Sakuraya, Hideki Ushiku, Kei Hosoda, Takeshi Naitoh, Keishi Yamashita, Hiroki Harada
Publikováno v:
Cancer Science
The clinical efficacy of DNA cytology test (CY) in gastric cancer (GC) has been retrospectively proposed using cancer‐specific methylation of cysteine dioxygenase type 1 (CDO1). We confirmed the clinical utility of DNA CY in a prospective cohort. F
Autor:
Bingqing Yan, Siwei Zhang, Fangjia Tong, Huanhuan Xie, Lianhao Song, Lanlan Wei, Bozhi Wang, Tianyang Liu, Siyang Yu, Fen Ma
Publikováno v:
Cancer Science
Human papillomavirus (HPV) is an important etiological factor of head and neck squamous cell carcinoma (HNSCC). HPV+ HNSCC patients usually have a better prognosis, which probably results from the higher infiltration of B lymphocytes. This study was
Autor:
Aeneas Kolev, Magnus Starkhammar, Linda Marklund, Lars-Olaf Cardell, Eric Hjalmarsson, Gregori Margolin, Eva Munck-Wikland, Susanna Kumlien Georén, Pedro Farrajota Neves da Silva, Åsa Kågedal, Alexandra Elliot, Krzysztof Piersiala
Publikováno v:
Cancer Science
Anticancer immunotherapies have revolutionized cancer management, yet the effect of systemic anti‐programmed cell death protein 1 (PD‐1) treatment is predominantly studied in tumor‐infiltrating lymphocytes (TILs). Its impact on PD‐1 expressin
Autor:
Ririno Honma, Naoya Sakamoto, Shoichi Ukai, Hideki Ohdan, Kazuhito Naka, Daiki Taniyama, Wataru Shimizu, Kenji Harada, Wataru Yasui, Yuji Takakura, Takao Hinoi, Ryota Maruyama
Publikováno v:
Cancer Science
5‐Fluorouracil (5‐FU) is one of the most frequently used pharmacological agents in the treatment of colorectal cancer (CRC). Resistance to chemotherapy is a major cause of treatment failure of CRC, and it is a well known fact that cancer stem cel